Login to Your Account

Humacyte clinches $150M B round for human acellular vessel

By Amanda Pedersen
Senior Staff Writer

Tuesday, October 20, 2015
A biotechnology company developing an alternative to current dialysis access products raised $150 million in a committed series B preferred stock financing, making it the largest B round this year, according to BioWorld Snapshots.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription